Duowell Indications/Uses

Duowell Tablet should be used in patients treated simultaneously with both ingredients (Telmisartan and Rosuvastatin).
Telmisartan: Essential Hypertension.
Risk reduction of Cardiovascular disease: Telmisartan is indicated to reduce the risk of death from myocardial infarction, stroke and cardiovascular disease in patients 55 years or older at high risk of developing major cardiovascular events who cannot tolerate an angiotensin converting enzyme inhibitor (ACEI).
High risk of cardiovascular events includes evidence of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack, or diabetes mellitus with evidence of end-organ damage.
Rosuvastatin: Primary Hypercholesterolemia (Type IIa including heterozygous familial hypercholesterolemia) and combined hyperlipidemia (Type IIb): Adjuvant to diet when uncontrollable by diet and exercise.
Adjuvant to diet for homozygous familial hypercholesterolemia or other lipid-lowering treatments (e.g., LDL apheresis).
Slowing progression of atherosclerosis through lowering total-C and LDL-C to target level in hypercholesterolemia patients.
Adjuvant to diet of the patients who have primary dysbetalipoproteinemia (Type III).
Risk reduction of cardiovascular disease: in individuals without clinically evident coronary heart disease but age ≥50years old in men and ≥60 years old in women with hsCRP (high sensitive C-reactive protein) ≥2 mg/L and with at least one additional cardiovascular disease risk factor (ex: hypertension, low HDL-cholesterol, smoking or a family history of premature coronary heart disease etc.): reduce the risk of stroke; reduce the risk of myocardial infarction; reduce the risk of arterial revascularization.